期刊文献+

高糖环境下mircoRNA-200b影响视网膜血管内皮细胞功能的机制研究 被引量:1

Effect of micro RNA-200b on function of retinal endothelial cells under high-glucose environment and related mechanism
下载PDF
导出
摘要 目的探讨高糖环境下micro RNA-200b(mi R-200b)影响人视网膜血管内皮细胞(h RECs)功能的作用机制。方法在正常和高糖环境下培养h RECs,实时荧光定量聚合酶链式反应检测mi R-200b表达。分别用mi R-200b和特异性mi R-200b抑制剂转染h RECs,并且用噻唑蓝法检测高糖环境下mi R-200b对h RECs增殖的影响。用Western blot测定h RECs转染mi R-200b和mi R-200b抑制剂后对血管内皮生长因子(VEGF)、转化生长因子-β1(TGF-β1)蛋白和m RNA的表达的影响。结果高糖组VEGF、TGF-β1 m RNA和蛋白表达较对照组增加(P<0.05)。转染mi R-200b后,h RECs中mi R-200b表达升高,而VEGF、TGF-β1 m RNA和蛋白的表达降低。与高糖组比较,h RECs增殖受到抑制(P<0.05)。结论 mi R-200b通过改变VEGF和TGF-β1的表达,调节h RECs生长和增殖,延缓糖尿病视网膜病变的发生、发展。 Objective To investigate the effect of mleroRNA-200b (miR-200b) on human retinal endothe- lial cells (hRECs) under high-glucose environment and its mechanism. Methods hRECs were cultured under high-glucose or normal environment. Real time PCR was applied to detect miR-200b expression, miR-200b was transfected to hRECs and MTT was used to detect its effect on hRECs proliferation under high-glucose environment. Real time PCR and Western blot were performed to determine VEGF and TGF-β1 expressions in the retina endothelial cells. Results Compared with the normal control group, VEGF and TGF-β1 mRNA and protein expressions increased markedly in the high-glucose group (P〈 0.05). After miR-200b transfection, miR-200b expression increased in the hRECs, while VEGF and TGF-β1 mRNA and protein expressions decreased obviously. Compared with the high-glucose group, hRECs proliferation was inhibited (P 〈 0.05). Conclusions miR-200b can regulate the growth and proliferation of RECs by changing VEGF and TGF-β1 expression and delay diabetic retinopathy.
出处 《中国现代医学杂志》 CAS 北大核心 2016年第17期23-28,共6页 China Journal of Modern Medicine
基金 湖南省科技厅项目(No:2014TT2024、2012TT2029)
关键词 糖尿病视网膜病变 视网膜血管内皮细胞 血管内皮生长因子 转化生长因子Β1 diabetic retinopathy retinal endothelial cell VEGF TGF-β1
  • 相关文献

参考文献27

  • 1ANTONETTI D A, KLEIN R, GARDNER T W. Mechanisms ofdisease diabetic retinopathy[J]. N Engl J Med, 2012, 366(13): 1227-1239.
  • 2MYSONA B A, MATRAGOON S, STEPHENS M, et at. Imbal- ance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy[J]. Biomed Res Int, 2015, 15(8): DOI: 10.1155/2015/571456.
  • 3PARK Y H, SHIN J A, HAN J H, et al. The association between chronic kidney disease and diabetic retinopathy: the Korea na- tional health and nutrition examination survey 2008-2010 [J]. PLoS One, 2015, 10(4): 353-381. .
  • 4BOYNTON G E, STEM M S, KWARK L, et al. Multimodal char- acterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure[J]. Ophthalmology, 2015, 122(5): 957-967.
  • 5GARCIA de LA TORRE N, FERNANDEZ-DURANGO R, GOMEZ R, et al. Expression of angiogenic microRNAs in en- dothelial progenitor ceils from type 1 diabetic patients with and without diabetic retinopathy[J]. Invest Ophlhalmol Vis Sci, 2015, 56(6): 4090-4098.
  • 6SAVAGE S R, MCCOLLUM G W, YANG R, et al. RNA-seq i- dentifies a role for the PPAR beta/delta inverse agonist GSK0660 in the regulation of TNFalpha-induced cytokine signaling in reti- nal endothelial cells[J]. Mol Vis, 2015, 21: 568-576.
  • 7LOUKOVAARA S, GUCCIARDO E, REPO P, et al. Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopa- thy[J]. Acta Ophthalmol, 2015, 93(6): 512-523.
  • 8ORANG A V, BARZEGARI A. MieroRNAs in eoloreetal cancer: from diagnosis to targeted therapy[J]. Asian Pac J Cancer Prev, 2014, 15(17): 6989-6999.
  • 9GANDHI N S, TEKADE R K, CHOUGULE M B. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemo- therapeutic agents for cancer therapy: current progress and ad- vances[J]. J Control Release, 2014, 194: 238-256.
  • 10张潍,张伟,王辉,刘伟良,张晋,乔哲.miRNA-141、miRNA-145在非小细胞肺癌中的表达及与临床病理的关系[J].西安交通大学学报(医学版),2015,36(3):368-372. 被引量:22

二级参考文献52

  • 1JEMAL A,SIGEL R,WARD E,et al.Cancer Statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
  • 2JEMAL A,SIGEL R,WARD E,et al.Cancer Statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
  • 3LAM TK,SHAO S,ZHAO Y,et al.Influence of quercetinrich food intake on microRNA expression in lung cancer tissues[J].Cancer Epidemiol Biomarkers Prev,2012,21(12):2176-2184.
  • 4KROH EM,PARKIN RK,MITCHELL PS,et al.Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR(qRT-PCR)[J].Methods,2010,50(4):298-231.
  • 5BEREZIKOV E,GURYEV V,VANDE BELT J,et al.Phylgdenetic shadowing and computational identification of human microRNA genes[J].Cell,2005,120(1):21-24.
  • 6SMALL EM,FROST RJ,OLSON EN,et al.MicroRNAs and new dimension to cardiovascular disease[J].Circulation,2010,121(18):1022-1032.
  • 7DAVALOS V,ESTELLER M.MicroRNAs and cancer epigenetics:a macroevolution[J].Curr Opin Oncol,2010,22(1):35-45.
  • 8LIN PY,YU SL,YANG PC.MincroRNA in lung cancer[J].Br J Cancer,2010,103(8):1144-1148.
  • 9CALIN GA,CROCE CM.MicroRNA signatures in human cancers[J].Nat Rev Cancer,2006,6(11):857-866.
  • 10MITCHELL PS,PARKIN RK,KRON EM,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc NatlAcad Sci USA,2008,105(30):10513-10518.

共引文献171

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部